JP2007509150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509150A5 JP2007509150A5 JP2006536701A JP2006536701A JP2007509150A5 JP 2007509150 A5 JP2007509150 A5 JP 2007509150A5 JP 2006536701 A JP2006536701 A JP 2006536701A JP 2006536701 A JP2006536701 A JP 2006536701A JP 2007509150 A5 JP2007509150 A5 JP 2007509150A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- compound according
- group
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- -1 methoxy, hydroxyl Chemical group 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000017164 Chronobiology disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 230000007659 motor function Effects 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 208000027753 pain disease Diseases 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 229940089973 Sodium channel antagonist Drugs 0.000 claims 1
- 206010059612 Tobacco withdrawal symptoms Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 229950005506 acetylmethadol Drugs 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000472 muscarinic agonist Substances 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- 229940072228 neurontin Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- 239000003402 opiate agonist Substances 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51304603P | 2003-10-21 | 2003-10-21 | |
| PCT/US2004/034466 WO2005041971A1 (en) | 2003-10-21 | 2004-10-15 | Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509150A JP2007509150A (ja) | 2007-04-12 |
| JP2007509150A5 true JP2007509150A5 (enExample) | 2007-11-22 |
Family
ID=34549245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536701A Withdrawn JP2007509150A (ja) | 2003-10-21 | 2004-10-15 | 神経障害性疼痛の治療において有用なトリアゾロ−ピリダジン化合物および、この誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070213338A1 (enExample) |
| EP (1) | EP1677799A4 (enExample) |
| JP (1) | JP2007509150A (enExample) |
| CN (1) | CN1871008A (enExample) |
| AU (1) | AU2004285452A1 (enExample) |
| CA (1) | CA2542536A1 (enExample) |
| WO (1) | WO2005041971A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| ATE463495T1 (de) * | 2005-09-27 | 2010-04-15 | Hoffmann La Roche | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten |
| DE102006029447A1 (de) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| CA2677493A1 (en) * | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
| WO2009000038A1 (en) * | 2007-06-28 | 2008-12-31 | Cnsbio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
| EP3106166B1 (en) | 2008-02-29 | 2020-12-02 | VM Therapeutics LLC | Compounds for treating pain syndrome and other disorders |
| US8993808B2 (en) * | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| WO2011035941A1 (en) | 2009-09-25 | 2011-03-31 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| RS55348B1 (sr) | 2010-04-19 | 2017-03-31 | Oryzon Gnomics S A | Inhibitori lizin specifične demetilaze-1 i njihova upotreba |
| DK2598482T3 (en) | 2010-07-29 | 2018-06-14 | Oryzon Genomics Sa | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE |
| EP2598480B1 (en) | 2010-07-29 | 2019-04-24 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| WO2012129491A1 (en) * | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Trpv3 modulators |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
| WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| AU2012324803B9 (en) | 2011-10-20 | 2017-08-24 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| CN103214488A (zh) * | 2012-01-21 | 2013-07-24 | 内蒙古民族大学 | 喹啉酮衍生物和以该化合物为活性成份的药物组合物及其制备方法 |
| WO2014069626A1 (ja) * | 2012-11-01 | 2014-05-08 | 協和発酵キリン株式会社 | ピリミドジアゼピノン化合物の製造方法 |
| CN106854207B (zh) * | 2015-12-08 | 2019-10-29 | 上海赛默罗生物科技有限公司 | 呔嗪类衍生物、其制备方法、药物组合物和用途 |
| CN107344936B (zh) * | 2016-05-06 | 2022-06-03 | 上海赛默罗生物科技有限公司 | 三唑哒嗪类衍生物、其制备方法、药物组合物和用途 |
| US20200270237A1 (en) * | 2017-10-19 | 2020-08-27 | Esteve Pharmaceuticals, S.A. | New alkoxyamino compounds for treating pain and pain related conditions |
| IL309843B2 (en) * | 2018-05-30 | 2026-05-01 | Praxis Prec Medicines Inc | History of [4,2,1]triazolo[3,4-a]pyridines and their use as sodium ion channel modulators |
| CN112979655A (zh) * | 2019-12-16 | 2021-06-18 | 上海赛默罗生物科技有限公司 | 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| CN114591352B (zh) * | 2022-05-11 | 2022-09-09 | 上海赛默罗生物科技有限公司 | 一种三唑并哒嗪类化合物及其应用 |
| EP4279074A1 (en) * | 2022-05-19 | 2023-11-22 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Azolo compounds for treatment of fibrotic diseases |
| WO2024059220A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001090108A1 (en) * | 2000-05-24 | 2001-11-29 | Merck Sharp & Dohme Limited | 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors |
| GB0028583D0 (en) * | 2000-11-23 | 2001-01-10 | Merck Sharp & Dohme | Therapeutic compounds |
-
2004
- 2004-10-15 US US10/575,942 patent/US20070213338A1/en not_active Abandoned
- 2004-10-15 AU AU2004285452A patent/AU2004285452A1/en not_active Abandoned
- 2004-10-15 CN CNA2004800306505A patent/CN1871008A/zh active Pending
- 2004-10-15 CA CA002542536A patent/CA2542536A1/en not_active Abandoned
- 2004-10-15 EP EP04795608A patent/EP1677799A4/en not_active Withdrawn
- 2004-10-15 JP JP2006536701A patent/JP2007509150A/ja not_active Withdrawn
- 2004-10-15 WO PCT/US2004/034466 patent/WO2005041971A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2478799A1 (en) | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| CA2470519A1 (en) | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | |
| AU2009228645B2 (en) | Hydroxymethylcyclohexyl amines | |
| JP2006522128A5 (enExample) | ||
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| WO2007056300A3 (en) | Methods and compositions for the treatment of brain reward system disorders by combination therapy | |
| CA2470612A1 (en) | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 | |
| EP2548568A3 (en) | Melanocortin receptor ligands | |
| WO2008126732A1 (ja) | 縮合二環式ヘテロアリール誘導体 | |
| PL211340B1 (pl) | Pochodne (imidazol-1-ilometylo)pirydazyny, lek zawierający te pochodne, sposób wytwarzania i zastosowanie tych pochodnych | |
| WO2004089366A8 (en) | Bicyclic compounds as nr2b receptor antagonists | |
| TW200817351A (en) | Aminoindan derivative or salt thereof | |
| JP2007530694A5 (enExample) | ||
| US12391664B2 (en) | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | |
| JPWO2011013623A1 (ja) | インドール誘導体、またはその薬理学的に許容される塩 | |
| JP2003503449A (ja) | 偏頭痛の処置のための選択的なｉＧｌｕＲ５受容体拮抗薬 | |
| JP2008505107A5 (enExample) | ||
| NZ592543A (en) | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| JP2005518439A5 (enExample) | ||
| FI89481C (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva 1-aminobut-3-enfoereningar | |
| WO2006057950A3 (en) | 4-phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | |
| JP2007512341A5 (enExample) | ||
| CN101910126B (zh) | 作为大麻素受体之配体的脯氨酸类似物 | |
| JP2010521520A5 (enExample) | ||
| JP4402957B2 (ja) | ５−（ピリジン−３−イル）−１−アザビシクロ［３．２．１］オクタン誘導体類、それらの製造と治療におけるそれらの適用 |